Role and regulation of FOXO transcription factors in development of breast cancer and drug resistance.

Project Information

FOXO BREAST CANCER

Grant agreement ID: 22951

Project closed

Start date 1 November 2005

End date 31 July 2006

Funded under

• Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006

Total cost No data

EU contribution € 159 613,00

Coordinated by

IMPERIAL COLLEGE OF LONDON
United Kingdom

Objective

To examine if FOXO expression and activity are regulated by chemotherapeutic agents (eg. cisplatin and taxol) in breast cancer cell lines

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance
• medical and health sciences › clinical medicine › oncology › breast cancer

You need to log in or register to use this function

Keywords

• Any-PI-3kinase
• FOXO
• Forkhead
• apoptosis
• breast cancer
• cell cycle
• endocrinology
• estrogen receptor
• molecular mechanism
• signalling
• transcription factor

Programme(s)

• FP6-MOBILITY - Human resources and Mobility in the specific programme for research, technological development and demonstration "Structuring the European Research Area" under the Sixth Framework Programme 2002-2006

Topic(s)

• MOBILITY-2.1 - Marie Curie Intra-European Fellowships (EIF)

Call for proposal

FP6-2004-MOBILITY-5
See other projects for this call

Funding Scheme

EIF - Marie Curie actions-Intra-European Fellowships

Coordinator

IMPERIAL COLLEGE OF LONDON

• EU contribution: No data
• Address: Exhibition Road, South Kensington ; LONDON ; United Kingdom
• Total cost: No data